EPIC-Knee study now available at ClinicalTrials.gov

Episurf Medical (NASDAQ: EPIS B) announces that the company’s clinical study EPIC-Knee: Episealer® Knee System IDE Clinical Study now has been published on ClinicalTrials.gov, the largest clinical trial database in the world. The study summary, giving information about the study design and outcome measures can be found at the link below:

https://clinicaltrials.gov/ct2/show/NCT04000659?term=episurf&rank=1

The study is a randomised controlled trial with 180 subjects. The webpage will be continuously updated as the study progresses.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: